AGR2 and neoplasm: Given the need to develop new therapeutics for PDAC and the substantial body of evidence implicating AGR2 in PDAC and other tumor types, we set out in this study to characterize AGR2 expression in primary PDAC samples and model systems, demonstrate its role in the motility of PDAC cells, and to develop a novel and high-affinity anti-AGR2 antibody that could be used for therapy.